-
Triazole ALDH2 Activators in Myocardial Ischemia
2026-09-08
This 2025 ACS Medicinal Chemistry Letters study used molecular simulation, chemical optimization, and mouse ischemia–reperfusion testing to identify triazole aldehyde dehydrogenase 2 activators. Lead compound Z17 combined improved water solubility with strong ALDH2 activation and measurable protection of cardiac function and myocardial tissue in a preclinical model.
-
Forskolin: Practical cAMP Assay Workflows
2026-09-08
Build reproducible cAMP experiments with Forskolin, from solvent-aware preparation to orthogonal functional validation. Its direct adenylate cyclase activation supports differentiated stem-cell, neuroendocrine, inflammatory, and cardiovascular disease research workflows.
-
S63845 MCL1 Inhibitor: Applied Apoptosis Workflows
2026-09-07
S63845 converts MCL1 dependence into a measurable mitochondrial apoptosis phenotype, making it useful for dose–response studies, mechanistic validation, and hematological cancer models. This guide pairs practical handling and assay design with LACTB-focused mitochondrial remodeling insights from a recent reference study.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-09-07
This reference study identifies SIRT6-AMPK signaling as a mechanistic link between metabolic stress, NLRP3 inflammasome activation, atrial remodeling, and angiotensin II-induced atrial fibrillation. Using human atrial samples, bioinformatics, a murine Ang II model, and SIRT6 gain- and loss-of-function experiments, it shows that berberine suppresses inflammatory and fibrotic remodeling through this pathway.
-
CircRHOBTB3–NONO–MAOA Axis in Prostate Cancer
2026-09-05
The reference study identifies circRHOBTB3 as a tumor-suppressive circular RNA that limits prostate cancer proliferation and metastasis by retaining NONO in the cytoplasm and reducing MAOA transcription. Its integrated analysis of circRNA expression, protein localization, transcriptional regulation, and circularization provides a mechanistic framework for biomarker and therapeutic research in metastatic prostate cancer.
-
Reactive Oxygen Species Assay Kit: DHE Workflow
2026-09-04
Build a quantitative intracellular superoxide workflow for living cells, from chondrocyte oxidative-stress models to apoptosis research. This practical guide combines DHE assay controls, optimization parameters, and mechanistic interpretation inspired by the PQQ–Nrf2–IGF1R osteoarthritis study.
-
HotStart qPCR Master Mix for Listeria Biofilms
2026-09-04
Discover how HotStart Universal 2X FAST Green qPCR Master Mix can connect hly-dependent biofilm phenotypes with reliable gene expression analysis. This article presents a practical assay strategy for distinguishing transcriptional regulation, DNA abundance, and nonspecific fluorescence in Listeria monocytogenes research.
-
Gastrin I (human) in Organoid Assays
2026-09-03
Gastrin I (human) provides a controllable CCK2-receptor stimulus for gastric acid secretion pathway research, parietal-cell assays, and receptor-positive gastrointestinal models. This guide connects peptide handling with hiPSC-derived organoid workflows while highlighting model selection, assay design, and troubleshooting limits.
-
BRD4 Inhibitors Sensitize Cells to Erastin Ferroptosis
2026-09-03
Fan et al. show that pharmacological BRD4 inhibition and BRD4 depletion broadly enhance erastin-induced ferroptosis across five cell lines. The study identifies increased reactive oxygen species and reduced FSP1 expression as shared features, supporting combined BET and ferroptosis targeting in FSP1-dependent cancer models.
-
Lycopene, ERK, and DON-Induced Gut Barrier Injury
2026-09-02
The 2025 reference study identifies ERK signaling as a mechanistic link between deoxynivalenol-induced oxidative and inflammatory injury, intestinal barrier dysfunction, and NLRP3 inflammasome activation. In an IPEC-J2 cell model, lycopene reversed these changes, while pharmacological ERK activation weakened the protection, supporting ERK as a candidate target for further mycotoxin-toxicity research.
-
Q-VD-OPh: Reading Apoptosis Beyond Caspase Assays
2026-09-02
Q-VD-OPh is a cell-permeable pan-caspase inhibitor that can help separate mitochondrial apoptosis initiation from downstream execution. This mechanistic guide connects BAX–BAK pore biology with assay design, cell viability workflows, and Alzheimer’s disease research.
-
5-Azacytidine Workflows for Leukemia Epigenetics
2026-09-01
Build reproducible DNA methylation experiments with 5-Azacytidine, from concentration-finding and gene-reactivation assays to leukemia-focused mechanism studies. Its value is greatest as a DNMT benchmark that can distinguish epigenetic effects from the dual tubulin–DNMT activity reported for the novel compound H62.
-
Reactive Oxygen Species Assay Kit for Mitophagy
2026-09-01
Learn how the Reactive Oxygen Species Assay Kit and dihydroethidium (DHE) probe can connect intracellular superoxide measurement with mitophagy and pulmonary fibrosis research. This guide emphasizes mechanism-driven assay design, controls, interpretation, and the limitations of fluorescence-based ROS analysis.
-
Annexin V-PE Reagent for CD38 CAR-T Assays
2026-08-31
Use Annexin V-PE Reagent to convert phosphatidylserine exposure into a rapid readout of target-cell killing, CAR-T fratricide, and assay-state transitions. The workflow pairs early apoptosis marker detection with structure-guided CD38 binder comparisons, adding kinetic and mechanistic resolution beyond a single viability endpoint.
-
Carfilzomib Sensitizes ESCC to Iodine-125 Radiation
2026-08-31
A 2025 Translational Oncology study shows that carfilzomib strengthens iodine-125 seed radiation against esophageal squamous cell carcinoma by intensifying endoplasmic reticulum stress and engaging apoptosis, paraptosis, and ferroptosis. The work provides a mechanistic framework for overcoming brachytherapy resistance, while also identifying the need to distinguish overlapping cell-death pathways experimentally.